Amgen Re-Ups On miRagen

Amgen Ventures, the venture capital arm of Thousand Oaks-based Amgen, has re-upped on an investment in a biopharmaceuticals developing microRNA-based treatments for cardiovascular and muscle disease. According to miRagen Therapeutics, it has raised $20M in a Series B, which was led by Remeditex Ventures, and also included Amgen--an existing investor sin the company--along with Atlas Venture, Boulder Ventures Ltd., and Broadview Ventures. miRagen is based in Boulder, Colorado. More information »